FINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY

Transcription

1 Arthroplasty Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events FINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY D. Warwick, R. J. Friedman, G. Agnelli, E. Gil-Garay, K. Johnson, G. FitzGerald, F. M. Turibio From the Global Orthopaedic Registry D. Warwick, MD, FRCS, FRCS(Orth), Consultant Orthopaedic Surgeon University of Southampton, Southampton, Hampshire SO16 6UY, UK. R. J. Friedman, MD, FRCS(C), Orthopaedic Surgeon Charleston Orthopaedic Associates, 7 Ashley Crossing Drive, Suite 11, Charleston, South Carolina 9414, USA. G. Agnelli, MD, Professor of Internal Medicine Department of Internal Medicine, Division of Internal and Vascular Medicine, Stroke Unit University of Perugia, 613 Perugia, Italy. E. Gil-Garay, MD, Orthopaedic Surgeon Hospital Universitario La Paz, Madrid 836, Spain. K. Johnson, MD, Orthopaedic Surgeon University of Massachusetts Memorial Health Care, 33 Oak Avenue, Worcester, Massachusetts 165, USA. G. FitzGerald, MD, Biostatistician Center for Outcomes Research University of Massachusetts Medical School, 365 Plantation Street, Suite 185, Worcester, Massachussets 165, USA. F. M. Turibio, MD, Orthopaedic Surgeon Hospital Santa Marcelina, Rua Cantagalo 447, São Paulo, SP 3319-, Brazil. Correspondence should be sent to Mr D. Warwick; djwarwick@compuserve.com 7 British Editorial Society of Bone and Joint Surgery doi:1.13/31-6x.89b $. J Bone Joint Surg [Br] 7;89-B: Received 1 November 6; Accepted 11 January 7 Patients who have undergone total hip or knee replacement (THR and TKR, respectively) are at high risk of venous thromboembolism. We aimed to determine the time courses of both the incidence of venous thromboembolism and effective prophylaxis. Patients with elective primary THR and TKR were enrolled in the multi-national Global Orthopaedic Registry. Data on the incidence of venous thromboembolism and prophylaxis were collected from 6639 THR and 836 TKR patients. The cumulative incidence of venous thromboembolism within three months of surgery was 1.7% in the THR and.3% in the TKR patients. The mean times to venous thromboembolism were days (SD.5) for THR, and 9.7 days (SD 14.1) for TKR. It occurred after the median time to discharge in 75% of the THR and 57% of the TKA patients who developed venous thromboembolism. Of those who received recommended forms of prophylaxis, approximately one-quarter (6% of THR and 7% of TKR patients) were not receiving it seven days after surgery, the minimum duration recommended at the time of the study. The risk of venous thromboembolism extends beyond the usual period of hospitalisation, while the duration of prophylaxis is often shorter than this. Practices should be re-assessed to ensure that patients receive appropriate durations of prophylaxis. A high risk of venous thromboembolism after total hip replacement (THR) or total knee replacement (TKR) has long been appreciated. The reported incidence of asymptomatic deepvein thrombosis (DVT) lies between 41% and 85%. 1 For proximal DVT it is between 5% and 36% and for fatal pulmonary embolism, the reported incidence lies between.1% and 1.% in the absence of effective prophylaxis. 1 Previous studies have shown that the risk of venous thromboembolism continues for some time after surgery. In a study of 499 patients who had undergone THR the peak onset of thrombosis was on the fourth post-operative day, with the period of elevated risk extended to at least day 18 after surgery. In THR and 4 59 TKR patients in California in whom the cumulative incidences of venous thromboembolism were.8% and.1%, respectively, the median time to diagnosis after surgery was 17 days for THR and seven days for TKR. 3 Although ostensibly 88% of these patients received in-hospital prophylaxis, 76% and 47% of venous thromboembolism events in the THR patients and TKR patients respectively, were diagnosed after discharge from hospital, and only 3% of the patients received outpatient prophylaxis. 3 An even longer duration of elevated risk was observed in a Norwegian study of THR and TKR patients who had received in-hospital prophylaxis for approximately ten days. 4 Symptoms of DVT appeared at a mean of 7 days after THR and 16 days after TKR. 4 Early studies have shown that prophylaxis between seven and 14 days reduces the risk of venous thromboembolism. 5-1 This length of time was chosen for use in trials based on the trials based on the then-average length of hospital stay as opposed to on physiology. These trials led to their data being used as evidence for consensus guideline recommendations from the American College of Chest Physicians in 1, stating that THR and TKR patients should receive prophylaxis for a minimum of seven to ten days. 11 Furthermore, metaanalyses of studies on prophylaxis with lowmolecular-weight heparin (LMWH) have shown that increasing the length of time to at least five weeks after THR and TKR further reduces the risk of venous thromboembolism, cutting clinical and asymptomatic event rates VOL. 89-B, No. 6, JUNE 7 799

2 8 D. WARWICK, R. J. FRIEDMAN, G. AGNELLI, E. GIL-GARAY, K. JOHNSON, G. FITZGERALD, F. M. TURIBIO by more than a half, without an increase in the risk of major bleeding While reports of the proportion of THR and TKR patients who receive any form of prophylaxis ranges from 88% to 1%, 3,15-17 the pattern of use of recommended forms of prophylaxis in relation to the time course of an elevated risk of venous thromboembolism has not yet been concurrently determined or reported. The Global Orthopaedic Registry records in-hospital treatment and clinical outcomes of consecutively-enrolled patients who have undergone elective THR or TKR. This multi-national registry reflects diverse, real-world, contemporary surgical practices and has, to date, collected data from 15 patients from 1 university-affiliated or community hospitals in 13 countries. In our study on data from this Registry, we aimed firstly to determine the time course of the occurrence of venous thromboembolic events in THR and TKR patients who had been operated on using contemporary surgical practices, and secondly, to ascertain whether these patients received prophylaxis, during the period in which they were at increased risk of venous thromboembolism, according to expert consensus group recommendations. Patients and Methods Design of the study. The study was designed and co-ordinated by the Center for Outcomes Research (University of Massachusetts, Worcester, Massachusetts) under the guidance of a Scientific Advisory Board. Participating surgeons enrolled consecutive patients who had undergone elective primary THR or TKR. Patients who underwent revision of previous surgery for a fracture of the hip or the knee were excluded. In-hospital data were collected for all patients. Data on selected aspects of out-patient management and post-discharge outcomes were collected after three and 1 months. The scientific co-ordinating Centre ensured that the registry complied with scientific and ethical standards. Approval for the study was obtained from local ethics committees or institutional review boards, as required. When required by each hospital s ethics review committee, signed informed consent was obtained from the patients before they participated in the registry. Collection of data. Participating surgeons and trained study co-ordinators used standard case report forms to collect data, including details of the patient, primary diagnosis, pre-existing comorbid conditions, the length of stay in hospital, the type of anaesthesia, venous thromboembolism prophylaxis (type and duration), in-hospital complications, discharge disposition and patient self-reported quality of life. Completed case report forms were sent to the scientific co-ordinating Centre for entry into the database and subsequent analysis. Data were double-key entered into a computer database and subsequently analysed using SAS-PC software version 9.1 (SAS Institute, Cary, North Carolina). The quality of the data was monitored using standardised query logic. Out-of-range or illogical responses were queried on a quarterly basis and corrections were faxed to the co-ordinating Centre. A DVT or pulmonary embolism, collectively referred to as a venous thromboembolism, was defined as a symptomatic event, subsequently confirmed by diagnostic imaging techniques including venography, ultrasound, radio-isotope scanning and three-dimensional (3D) CT. The dates on which clinically diagnosed symptomatic DVT or pulmonary embolism occurred were recorded. Two TKR and no THR patients died in hospital of pulmonary embolism (confirmed by autopsy). Only 5 patients died in hospital in total (9 THR and 16 TKR). Of the THR patients, one died of pulmonary embolism within three months of discharge (3 patients died post-discharge in total - 16 THR and seven TKR). The three fatal pulmonary embolisms are included in our analysis. Details of the patients and surgical practice. In total, 15 patients (6695 THR and 835 TKR) were enrolled in the Global Orthopaedic Registry from 1 hospitals (156 surgeons) in 13 countries (Australia, Brazil, Bulgaria, Canada, Colombia, Germany, Italy, Japan, Poland, Spain, Turkey, United Kingdom and USA) between June 1 and December 4. Data on the timing of venous thromboembolic events, or data required to determine the period of followup, had not been recorded for 145 patients and these patients were excluded, leaving a total of 6639 THR and 836 TKR patients for analysis. Overall, 74% (491) of the THR and 67% (556) of the TKR patients had follow-up data for at least three months. Of the patients, 46% (384) of THR and 6% (5135) of the TKR patients were enrolled in the USA. Details of the patients and surgery are shown in Table I. The table allows for the lack of some variables recorded on each patient s case report form. Compared with the THR patients, the TKR patients were similar in age, but were more likely to be women and to have a body mass index (BMI) over 3 kg/m. The TKR patients were also more likely to have a previous history of venous thromboembolism and tended to have a slightly shorter stay in hospital. However, a higher proportion of TKR patients were discharged to a rehabilitation centre than the THR patients. Statistical analysis. The Kaplan-Meier method was used to estimate the cumulative incidence rates of DVT and pulmonary embolism, and the median time to an event, starting from the day of surgery. The corresponding time course of the use of venous thromboembolism prophylaxis was determined by plotting the proportion of all patients with data available on day t who were receiving prophylaxis, against time. This estimated the time course of prophylaxis, assuming that it was the same for patients with in-hospital only data and those with in-hospital and post-discharge data. In the follow-up period, the duration of prophylaxis was determined by assuming that prophylaxis started on the day of surgery and continued without interruption for the duration specified in a patient s case report form. The median dura- THE JOURNAL OF BONE AND JOINT SURGERY

3 INSUFFICIENT DURATION OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT 81 Table I. Details of the patients undergoing total hip replacement (THR) or total knee replacement (TKR) and surgery Characteristic 6639 * THR 836 * TKR Median age in yrs (IQR ) 68 (57 to 75) 7 (63 to 76) Women (%) 59 (38/657) 66 (597/85) Median body mass index in kg/m (IQR) 7 (5 to 31) 3 (7 to 35) Body mass index > 3 kg/m (%) 3 (184/58) 51 (359/719) History of venous thromboembolism (%). (135/6639).9 (4/836) Median length of hospital stay in days (IQR) 5 (3 to 11) 4 (3 to 9) Patients discharged to rehabilitation centre or other 36 (35/6466) 4 (33/7993) facility (%) Patients discharged home (%) 64 (4157/6466) 58 (4663/7993) Any prosthesis component cemented (%) 41 (7/6639) 96 (7934/836) ASA classification (%) No chronic conditions (17/6367) 13 (15/774) Mild chronic problems 53 (3399/6367) 55 (433/774) Severe chronic problems 5 (166/6367) 31 (4/774) Incapacitating chronic problems or moribund 1 (9/6367) 1 (8/774) Anaesthesia (%) General alone 48 (398/65) 37 (978/847) General plus other 4 (9/65) 7 (55/847) Other alone 48 (313/65) 56 (4517/847) * denominators vary as not all variables were recorded on each patient s case report form n = 6594 THR and 8167 TKR patients; IQR, interquartile range n = 58 THR and 719 TKR patients n = 6584 THR and 8158 TKR patients ASA, American Society of Anesthesiologists tion of the prophylaxis and the interquartile range (IQR) were calculated using data from only those patients who had been followed up at three months or more. For those who received intermittent pneumatic compression in combination with either LMWH or warfarin, the duration of prophylaxis was defined as the duration of either LMWH or warfarin or intermittent pneumatic compression, whichever was the longest. For this paper, the duration of individual forms of prophylaxis was only calculated for LMWH, warfarin, and intermittent pneumatic compression, since only these were recommended by the American College of Chest Physicians 11 at the time of this study. Prophylaxis was defined as any use of LMWH, warfarin, fondaparinux, unfractionated heparin or intermittent pneumatic compression. In order to relate the time course of thromboembolic events to the recommended duration of prophylaxis we took into account three time points. These included, the median length of hospital stay, the seventh day after surgery (the end of the minimum duration of prophylaxis recommended by the sixth American College of Chest Physicians guidelines for the prevention of venous thromboembolism in 1 11 ) and the 8th day after surgery (the end of the minimum duration of prophylaxis recommended for THR patients by the seventh American College of Chest Physicians guidelines in 4). 1 A univariate Cox regression was performed to identify factors associated with an increased incidence of thromboembolism after surgery. All patients in this analysis received some form of prophylaxis. The characteristics considered included the type of surgery (THR or TKR), the American Society of Anesthesiologists (ASA) physical status classification, gender, BMI above 3 kg/m, age (years in increasing intervals), type of anaesthesia, previous venous thromboembolism, ischaemic heart disease and venous stasis syndrome. Factors associated with an increased incidence of thromboembolism (significance at p.5) were considered for inclusion in a Cox multiple-regression model. The model adjusts for the length of hospital stay and country. Factors which remained in the model and were statistically significant (p.5) were considered to be independent predictors of venous thromboembolism after surgery. Results Incidence and factors associated with venous thromboembolism. The cumulative incidence of thromboembolism in the patients with data on the timing of thromboembolic events was.%. Of the 6639 THR patients, 76 experienced a DVT within three months of surgery at a mean of.5 days (6 to 37, SD 3.3) after surgery, while 11 had a pulmonary embolism at a mean of 14.3 days ( to 31, SD 14.) after surgery (Table VOL. 89-B, No. 6, JUNE 7

4 8 D. WARWICK, R. J. FRIEDMAN, G. AGNELLI, E. GIL-GARAY, K. JOHNSON, G. FITZGERALD, F. M. TURIBIO Table II. Number of venous thromboembolism (VTE) events and timing after total hip replacement (THR) and total knee replacement (TKR) Thromboembolic event * 6639 THR 836 TKR Total number of Median time (IQR ) thromboembolic events after surgery, days Total number of thromboembolic events Median time (IQR) after surgery, days DVT (6 to 37) (3 to 8) PE 11 5 ( to 31) (3 to 11) VTE (DVT or PE) 87 1 (5 to 36) 15 5 (3 to 9) * DVT, deep-vein thrombosis; PE, pulmonary embolism total number of symptomatic thromboembolic events that occurred after surgery and were later objectively confirmed IQR, interquartile range Table III. Univariate Cox analysis of the incidence (%) of venous thromboembolism (VTE) in * total knee replacement (TKR)/total hip replacement (THR) patients VTE incidence Factor In patients with factor In patients without factor Hazard ratio (95% CI) p-value (TKR vs THR) (%) 1.9 (15/86) 1.3 (87/6539) (1.16 to 1.96).3 Post-surgery (%) 1 days 4.9 (117/4).8 (4/156).38 (1.67 to 3.38) <.1 > 1 days.6 (33/564).9 (45/533).67 (.43 to ).8 ASA grade severe or worse (vs less than severe) 1.4 (59/4136) 1.8 (171/9673).9 (.74 to 1.9).7 (%) Previous VTE (%) 7.1 (6/369) (11/14 196) 4.46 (.97 to 6.7) <.1 Previous ischaemic heart disease (%).1 (41/195) 1.6 (196/1 615) 1.38 (.99 to 1.93).6 Previous venous stasis syndrome (%) 3.9 (3/59) (14/13 974).38 (5 to 3.66) <.1 Women vs men (%) 1.9 (166/8397) 1.3 (67/531) 1.46 (1.1 to 1.94).1 Body mass index > 3 kg/m (%) 1.9 (99/5343) 1.4 (95/77) 1.47 (1.11 to 1.94).1 Any hip/knee component cemented (%) 1.7 (18/1 377) 1.4 (57/4188) 1.7 (.94 to 1.71).1 Anaesthesia (%) Any general 1. (83/6755). (154/781).6 (.5 to.86). Any spinal. (137/6374) 1. (1/8191) 1.67 (1.9 to.17) <.1 Epidural 1. (6/56) 1.8 (11/1 5).57 (.38 to.86).1 Lumbar plexus block 1.9 (4/14) 1.6 (33/14 351).97 (.36 to.59).94 * dates were not recorded for VTE occurrence in 3 patients and were missing for 115 patients. Of these left, 31 patients did not receive prophylaxis. The remaining patients were included in the analyses denominations vary since not all the variables were recorded on each patient s case report form CI, confidence interval ASA, American Society of Anesthesiologists this was not recorded for 15 patients II). The mean time to venous thromboembolism was days (5 to 36, SD.5). The cumulative incidence of venous thromboembolism within the three months after THR was 1.7%. An additional seven patients experienced a thromboembolic event after THR, but the dates on which the events occurred had not been recorded. If we assume that they had occurred during the three months after surgery and they are included, the cumulative incidence would have been 1.8%. Of the 836 TKR patients, 134 experienced a DVT during the three months after surgery at a mean of 9.5 days (3 to 8, SD 13.6) after surgery, while 18 had a pulmonary embolism at a mean of 1.7 days (3 to 11, SD 17.9) after surgery (Table II). The mean time to venous thromboembolism was 9.7 days (3 to 9, SD 14.1). The cumulative incidence of thromboembolism within the three months after TKR was.3%. An additional 3 patients had a thromboembolic event after TKR, but were excluded because the dates of occurrence had not been recorded. If it is assumed that these events occurred during the three months after surgery and they are included, the cumulative incidence would have been.6%. Factors which were associated with venous thromboembolism are shown in Table III. Consideration of these factors along with the patients country of origin in a multiple Cox regression model showed that previous venous thromboembolism (hazard ratio 4.9, 95% confidence interval (CI) 3.15 to 7.67) and BMI above 3 kg/m (hazard ratio 1.68, THE JOURNAL OF BONE AND JOINT SURGERY

5 INSUFFICIENT DURATION OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT 83 Patients receiving prophylaxis (%) % (n = 188) 4.6% (n = 757) 3.9% (n = 737) 33.5% (n = 134) USA (n = 384).1% (n = 4; warfarin only).3% (n = 1; IPC + warfarin) LMWH only IPC + LMWH only Warfarin only IPC + warfarin only 78.5% (n = 79) 11.4% (n = 44) Other participating countries (n = 3555) Region Fig. 1a Patients receiving prophylaxis (%) % (n = 393) 3.% (n = 164) 5.9% (n = 1331) 18.% (n = 96) USA (n = 5135).1% (n = ; Warfarin only).% (n = 5; IPC + warfarin) LMWH only IPC + LMWH only Warfarin only IPC + warfarin only 73.% (n = 69) 17.4% (n = 53) Other participating countries (n = 311) Region Fig. 1b Bar charts showing the types of prophylaxis received on the first day following a) total hip replacement and b) total knee replacement (LMWH, low molecular weight heparin; IPC, intermittent pneumatic compression). Cumulative VTE incidence (%) Fig. TKA THA Graph showing the cumulative incidence of venous thromboembolism (VTE) in patients after total hip replacement (THR; 6639) and total knee replacement (TKR; 836). 95% CI to.6) were independently associated with an increased risk of venous thromboembolism. In the univariate analysis (Table III), TKR surgery was also significantly associated with an increased incidence of venous thromboembolism compared with THR surgery. In the multiple Cox regression model, an interaction with time after surgery and type of surgery were also observed (p <.1), with a higher risk of thromboembolism after TKR during the early post-operative period and lower risk during the late post-operative period, compared with THR patients (hazard ratio.41, 95% CI 1.6 to 3.63 for TKR vs THR during the first ten days after surgery; hazard ratio.61, 95% CI.36 to 1.3 for TKR vs THR after ten days). Methods of venous thromboembolism prophylaxis. In total, of the patients (98%) received a pharmacological or mechanical form of prophylaxis with LMWH, warfarin, unfractionated heparin, fondaparinux or intermittent pneumatic compression on the first day after surgery. No prophylaxis was given to 31 patients. The use of prophylaxis varied by region and the type of surgery (Fig. 1). Surgeons commonly used warfarin for both THR and TKR patients in the USA either alone or combined with intermittent pneumatic compression, while in other countries, LMWH (either alone or combined with intermittent pneumatic compression) was most frequently used as a form of prophylaxis on the first day after surgery. It was more common to use intermittent pneumatic compression combined with warfarin or LMWH in the USA than in other countries. Patterns of prophylactic practice and incidence. In the THR patients, 65 of 87 (75%) thromboembolic events occurred after the median time to hospital discharge (five days after surgery, Fig. ). Of the THR patients who received any form of prophylaxis on the day after surgery, 796 of 538 (15%) were not receiving it five days after surgery (Fig. 3a). In the TKR patients, 86 of 15 (57%) thromboembolic events occurred after the median time to hospital discharge (four days after surgery, Fig. ). Of the TKR patients who received any form of prophylaxis on the day after surgery, 1% (68 of 6517) were not receiving it four days after surgery (Fig. 3b). In the THR patients, 54 of 87 (6%) thromboembolic events occurred after seven days while prophylaxis had been discontinued in 6% (139 of 5113) of those who had initially received any form of prophylaxis. At seven days after TKR surgery, 46 of 15 (3%) thromboembolism events were yet to occur while prophylaxis had been discontinued in 7% (1558 of 5763) of those who had initially received prophylaxis. In the THR patients, 6 of 87 (3%) thromboembolism events occurred after 8 days following surgery, while prophylaxis had been discontinued in 54% (484 of 4637) of those who had initially received prophylaxis. At the same time point after TKR surgery, only 11 of 15 (7%) thromboembolic events were yet to occur while 63% (319 of 596) of the TKR patients who initially received prophylaxis were no longer receiving it. VOL. 89-B, No. 6, JUNE 7

6 Cumulative VTE incidence (%) Cumulative VTE incidence (%) 84 D. WARWICK, R. J. FRIEDMAN, G. AGNELLI, E. GIL-GARAY, K. JOHNSON, G. FITZGERALD, F. M. TURIBIO Patients receiving prophylaxis (%)* Cumulative VTE 6 incidence Prophylaxis 1 (any type) Fig. 3a Patients receiving prophylaxis (%)* Cumulative VTE incidence Prophylaxis (any type) Graphs showing the time course of prophylactic use (any type) versus the cumulative incidence of venous thromboembolism (VTE) after a) total hip replacement and b) total knee replacement (*compared with prophylactic use on the day when most patients received it). Fig. 3b Cumulative VTE incidence (%) Patients receiving prophylaxis (%)* Cumulative VTE 6 incidence LMWH alone.5 Warfarin alone Fig. 4a Patients receiving prophylaxis (%)* Cumulative VTE incidence LMWH alone Warfarin alone Fig. 4b Cumulative VTE incidence (%) Graphs showing the time course of prophylactic use (low molecular weight heparin (LMWH) alone or warfarin alone) versus the cumulative incidence of venous thromboembolism (VTE) after a) total hip replacement and b) total knee replacement (* compared with prophylactic use on the day when most patients received it). The patterns of prophylactic use varied depending on the method used. In the THR patients who received LMWH alone, the time course of use was characterised by a slow and linear decrease from the time of surgery to about ten weeks after surgery; all THR patients who received LMWH received it up to the median time of hospital discharge and more than one-third were not receiving it 8 days after surgery (Fig. 4a). 1 By contrast, the use of warfarin alone in THR patients was characterised by a dramatic decrease around the time of hospital discharge. Prophylaxis with warfarin was discontinued in 4.5% (31 of 69) at day three, 66% (39 of 593) at day five, and 75% (47 of 571) at day seven. Of the THR patients who had received warfarin alone, 86% (443 of 518) were no longer receiving prophylaxis 8 days after surgery (Fig. 4a). The patterns of prophylactic use in the TKR patients were similar to those in the THR patients. Of the TKR patients who received LMWH alone, all were receiving it at the median time to hospital discharge and 4% (67 of 1689) were no longer receiving it 8 days after surgery (Fig. 4b). Of those receiving warfarin alone, 4% (417 of 148) and 74% (65 of 8) were no longer receiving prophylaxis at the median time to hospital discharge and 8 days after surgery, respectively (Fig. 4b). Compared with patients who received prophylaxis with LMWH alone, patients who received a combination of intermittent pneumatic compression and LMWH were less likely to continue to receive prophylaxis up to 8 days after surgery. Of the THR and TKR patients who received both intermittent pneumatic compression and LMWH, 8% (595 of 75) and 83% (175 of 13), respectively, were not receiving prophylaxis 8 days after surgery. By contrast, those who received warfarin alone were less likely to be receiving prophylaxis 8 days after surgery than patients THE JOURNAL OF BONE AND JOINT SURGERY

7 INSUFFICIENT DURATION OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT 85 who had received the combination of intermittent pneumatic compression and warfarin. Of the THR and TKR patients who had received both intermittent pneumatic compression and warfarin, 36% (36 of 853) and 3% (34 of 77) were not receiving it at the median time to hospital discharge, and 48% (36 of 745) and 56% (34 of 64) were not receiving prophylaxis 8 days after surgery, respectively. Discussion Our analyses of data from the Global Orthopaedic Registry confirm previous reports that the duration of the elevated risk of venous thromboembolism extended beyond the usual period of hospitalisation. 3,4,18,19 In our study, between one-third and one-half of thromboembolic events occurred after the median time to hospital discharge. Our study was the first to report both the incidence of venous thromboembolism and the use of recommended forms of prophylaxis concurrently, allowing us to determine the time course of both thromboembolic events and prophylactic use in the same group of patients. The duration of prophylaxis was often shorter than that recommended by evidence-based practice guidelines current at the time of the patients enrolment 11 and shorter than the period of risk of venous thromboembolism in THR and TKR patients. While nearly all patients received prophylaxis on the first day after surgery, more than a quarter were not receiving any form of prophylaxis seven days after surgery, which was the minimum duration specified by the American College of Chest Physicians guidelines published in Patients who received LMWH were most likely still to be receiving prophylaxis at any time during the course of the study. Nonetheless, approximately 37% of the THR patients initially receiving LMWH did not receive this form of prophylaxis up to 8 days after THR surgery, now recommended by the seventh American College of Chest Physicians guidelines. 1 By contrast, the duration of prophylaxis was shortest in the patients who had received warfarin with or without intermittent pneumatic compression. Our study suggested a higher cumulative incidence and an earlier occurrence of thromboembolism after TKR than THR as has been reported in some previous studies. By contrast, the study of THR and 4 59 TKR patients by White et al 3 showed a three-month cumulative incidence of thromboembolism which was higher after THR than after TKR (.8% vs.1%, p <.1). More recently, Bjornara, Gudmundsen and Dahl have produced similar figures, and a meta-analysis of data from randomised, controlled trials has shown a higher incidence of symptomatic thromboembolism after THR (1.4% to 4.3%) than after TKR (1.% to 1.4%). 1 The differences in incidence may be explained in part by different methodologies, the different surgical treatments, and the variable prophylactic practices at the times of these studies as well as by the regional differences. In addition, we cannot exclude the possibility that the type and regimen of prophylaxis used in TKR patients enrolled in our registry were less optimal than in the enrolled THR patients, especially during the early postoperative phase. Factors independently associated with an increased incidence of thromboembolism in our population were previous thromboembolism and a BMI of more than 3 kg/m. This accords well with other studies, 1-3 some of which have additionally reported poor ASA classification, increasing age, chronic heart failure, the individual surgeons practice, varicose veins and a lack of prophylaxis, as independent predictors of the risk of thromboembolism in this population.-4 We did not confirm this. Previous thromboembolism, obesity, and hospital stay with recent surgery have been shown to be risk factors in general, not only in orthopaedic patients. 5,6 Although the duration of prophylaxis in our study appeared to follow more appropriately the time course of thromboembolic events in TKR compared with THR, we stopped prophylaxis in a significant proportion of TKR patients before the median time of occurrence of thromboembolism, the time point when 5% of all thromboembolism events had still not occurred. From this it is clear that prophylactic practices in these patients are still to be improved. Clinical trial data support extended periods of prophylaxis in THR and TKR patients. 3,1,14 The evidence-based practice guidelines of 4 recommend prophylaxis for a minimum of ten days, 1 as opposed to seven days recommended in 1 11 in THR and TKR patients, and up to 8 to 35 days in THR patients. 1 Given that recommendations suggest prophylaxis be given to patients after discharge and that clinical trials have failed to show an increase in the risk of major bleeding associated with this practice, 1,14 postdischarge practices clearly need to be reviewed. This is particularly the case for surgeons using warfarin, to ensure that all patients receive the recommended forms of prophylaxis for a duration which will provide sufficient protection from thromboembolism. The lack of compliance with the recommendations for the duration of prophylaxis which we observed is likely to be related, at least partially, to the length of hospitalisation. We observed a marked decrease in the rate of prophylaxis around the median time to discharge. This was particularly notable for patients who received prophylaxis with warfarin alone. Another possibility could be that surgeons may not have all been aware of the significant post-discharge risk of thromboembolism in THR and TKR patients and the importance of providing appropriate prophylaxis during this period. Given that our study has demonstrated that the period of risk of thromboembolism extends well beyond the standard periods of hospitalisation presently, especially for THR patients, clinical practices should be changed to account for the need to protect patients with appropriate postdischarge prophylaxis. Eikelboom et al 1 demonstrated VOL. 89-B, No. 6, JUNE 7

8 86 D. WARWICK, R. J. FRIEDMAN, G. AGNELLI, E. GIL-GARAY, K. JOHNSON, G. FITZGERALD, F. M. TURIBIO that, extended-duration prophylaxis with LMWH reduced the risk of symptomatic thromboembolism, compared with a placebo or no prophylaxis, with the only cost being an increase in the incidence of minor bleeding. Changes in clinical practice could be achieved by educating surgeons whose responsibility it is to provide care during patient hospitalisation as well as to both physicians and nurses who may be involved in post-discharge care. For example, Durieux et al 7 observed an increase in compliance with thromboembolism prophylaxis guidelines from 8.8% to 94.9% in an orthopaedic department of a French teaching hospital when a computer-based clinical-decision support system was introduced. Furthermore, the use of computerised electronic alerts almost doubled the use of pharmacological prophylaxis in a hospital in the USA and resulted in a reduction in the risk of thromboembolism of 41% at 9 days. 8 Our data do not exclude the possibility that thromboembolism will occur in some patients despite the use of prophylaxis, either because of inappropriate doses, or as a result of delayed first dose. Notably, a previous analysis of this registry showed that two-thirds of surgeons aimed for a target international normalised ratio (INR) which was lower than that recommended as effective for venous thromboembolism prophylaxis (INR to 3). 9 Even in cases where surgeons aimed for an INR above, less than one-half achieved this target by day two after surgery. 9 In other cases, patients may be at particularly high risk of thromboembolism because of a predisposing factor, such as thrombophilia or cancer. 6 However, our data clearly demonstrate a need for the more effective use of prophylaxis. With the possibility that the participating surgeons in our study had a particular interest in the prevention of thromboembolism, they may not have been completely representative of surgeons worldwide. This could have resulted in an overestimation of the compliance of orthopaedic surgeons with prevention guidelines. However, the three-month follow-up was 74% for THR and 67% for TKR patients. This is considered to be acceptable for observational studies such as the Global Orthopaedic Registry and does not limit the strength of our conclusions. In conclusion, the risk of venous thromboembolism after THR or TKR extends well beyond the usual period of hospitalisation of patients. Current prophylactic practices do not often comply with evidence-based practice guidelines. Our study has shown that the duration of prophylaxis given to these patients is often much shorter than the period in which thromboembolic events occur after surgery. This worringly leaves many patients in danger of suffering a lateoccurring thromboembolic event which may have been prevented if effective prophylaxis had been used for a longer duration, most notably THR patients who have the longest duration of elevated risk of thromboembolism. Even the correct duration of prophylaxis may not give adequate protection from venous thromboembolism if an incorrect prophylactic method or incorrect dose regimen is used. Our data are consistent with recommendations made by internationally accepted expert consensus guidelines, such as those from the American College of Chest Physicians 1 and Nicolaides et al, 3 and organisations such as the House of Commons Select Committee on Health in the United Kingdom. 31 Health-care decision-makers and surgeons should re-assess practices of prevention of venous thromboembolism to ensure that THR and TKR patients receive recommended forms of prophylaxis for an appropriate period of time, not only during hospitalisation but also after discharge. Supplementary Material Details of the Global Orthopaedic Registry advisory committee are available with the electronic version of this article on our website at The Global Orthopaedic Registry is supported by an unrestricted educational grant from sanofi-aventis and is co-ordinated by the Center for Outcomes Research at the University of Massachusetts Medical School, Worcester, Massachusetts. The Registry is overseen by a Scientific Advisory Committee. Additional information about this registry, including a full list of the Advisory Committee members, is available on the website at We wish to acknowledge Tim Norris for editorial support while preparing this manuscript. The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article. References 1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 4;16(3 Suppl): Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg [Br] 1981;63- B: White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158: Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand ;71: Sagar S, Nairn D, Stamatakis JD, et al. Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet 1976;1: Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315: Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;6: Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 19 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991;6: Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 199;67: Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 199;35: Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 1;119(1 Suppl): Eikelboom JW, Quinlan DJ, Douketis JD. Extendend-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trial. Lancet 1;358: Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 1;85: Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 1;135: THE JOURNAL OF BONE AND JOINT SURGERY

9 INSUFFICIENT DURATION OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT Anderson FA Jr, Hirsh J, White K, et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty : findings from the Hip and Knee Registry. Chest 3;14(6 Suppl): Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 1;16: Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med ;16: Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement: a series of 116 cases with no routine chemical prophylaxis. J Bone Joint Surg [Br] 1995;77-B: Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg [Am] 1999;81-A: Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg [Br] 6;88-B: Schiff RL, Kahn SR, Shrier I, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest 5;18: Leizorovicz A, Turpie AG, Cohen AT, et al. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost 5;3: Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 3;99: Joseph JE, Low J, Courtenay B, et al. A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty. Br J Haematol 5;19: Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med ;16: Samama MM, Dahl OE, Quinlan DJ, Mismetti P, Rosencher N. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 3;88: Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA ;83: Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 5;35: Gallus A, Friedman R, Cushner F, et al. Prophylactic warfarin in clinical practice: treatment intensity when warfarin is used to prevent VTE after major joint surgery: findings from the Global Orthopedic Registry (GLORY) [abstract]. J Thromb Haemost 3;1: Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism International Consensus Statement (Guidelines according to scientific evidence). Int Angiol 6;5: No authors listed. House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. 5; (date last accessed 4 October, 6). VOL. 89-B, No. 6, JUNE 7